|Table of Contents|

Correlation between contrast-enhanced spectral mammography signs and different molecular subtypes of breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 21
Page:
4008-4014
Research Field:
Publishing date:

Info

Title:
Correlation between contrast-enhanced spectral mammography signs and different molecular subtypes of breast cancer
Author(s):
LI Hongen; XIE Hanmin; LYU Peifeng; LIN Xing; ZENG Yihui; ZHANG Yan
Department of Radiology，Guangdong Province Hospital for Women and Children Healthcare，Guangdong Guangzhou 511442，China.
Keywords:
contrast-enhanced spectral mammography; morphological features; breast cancer; molecular subtype
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.21.019
Abstract:
Objective:To explore the correlation between the imaging of contrast-enhanced spectral mammography（CESM) and different molecular subtypes of breast cancer.Method:44 cases of breast cancer patients diagnosed by pathology in our hospital was retrospectively analysed.All underwent CESM examination and immunohistochemical marker detection estrogen receptor（ER)，progesterone receptor（PR)，human epidermal growth factor receptor-2（HER-2) and cell proliferation antigen markers（Ki-67).According to the results of immunohistochemistry，breast cancer patients were divided into Luminal A，Luminal B，HER-2 overexpression type and triple negative type.The correlation analysis between the age，tumor size，morphology，microcalcification，spicule sign enhancement degree，enhancement density and molecular subtypes of CESM lesions was carried out.Result:Among the 44 patients with breast cancer，32 were invasive carcinoma，5 were intraductal carcinoma in situ，5 were invasive carcinoma with intraductal carcinoma in situ，1 was invasive carcinoma with papillary carcinoma，and 1 was intraductal carcinoma with papillary carcinoma.Luminal A，Luminal B，HER-2 overexpression type，and triple negative type were 10 cases（22.73%)，17 cases（38.64%)，10 cases（22.73%)，and 7 cases（15.90%)，respectively.There were no significant differences in age，tumor size，shape，microcalcification，burr sign，enhancement degree and enhancement density between breast cancer and CESM in different molecular subtypes（P>0.05).Pin-wise comparison:Luminal A and Luminal B had statistical significance in microcalcification（P<0.05).The intensity of reinforcement was statistically significant between Luminal B and triple negative（P<0.05).Conclusion:The morphological characteristics of breast cancer CESM can partially predict the molecular subtypes of breast cancer，and it has great reference value in the diagnosis,treatment and prognosis of breast cancer.

References:

［1］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73:17-48.
［2］王雯琼,杨蔚,刘开惠,等.乳腺X线摄影、MRI及病理联合诊断乳腺癌分子分型［J］.中国医学影像技术,2023,39(2):210-215. WANG WQ，YANG W，LIU KH，et al.Diagnosis of molecular typing of breast cancer by mammography，MRI and pathology［J］.Chin J Medical Imaging Technology,2023,39(2):210-215.
［3］张慧慧,都丽娜,伍建林.DCE-MRI与DWI直方图分析评估乳腺癌分子分型、预后和新辅助治疗的研究进展［J］.国际医学放射学杂志,2023,46(1):66-70. ZHANG HH，DU LN，WU JL.Evaluation of molecular typing，prognosis and neoadjuvant therapy by DCE-MRI and DWI histogram analysis［J］.International Journal of Medical Radiology,2023,46(1):66-70.
［4］孙笑芬,邢伟,俞胜男,等.对比增强能谱乳腺X线摄影对乳腺可疑钙化的诊断价值及其对外科治疗决策的影响［J］.中华医学杂志,2020,100(1):42-46. SUN XF，XING W，YU SN，et al.The diagnostic value of contrast-enhanced energy spectrum mammography in suspicious breast calcification and its influence on surgical treatment decision［J］.Chinese Medical Journal，2020100（1):42-46.
［5］吴芳,成静,曹春丽,等.不同分子分型乳腺癌超声弹性特征［J］.中国医学影像技术,2020,36(7):1017-1021. WU F，CHENG J，CAO CL，et al.Ultrasound elasticity characteristics of different molecular classification of breast cancer［J］.Chinese Journal of Medical Imaging Technology,2020,36(7):1017-1021.
［6］张倩,宋蕾,侯金香,等.不同分子分型的非特殊型浸润性乳腺癌超声及钼靶特征分析［J］.中国医学装备,2020,17(7):70-74. ZHANG Q，SONG L，HOU JX，et al.Analysis of ultrasonic and molybdenum target characteristics of non-specific invasive breast cancer with different molecular types［J］.Chinese Medical Equipment,2020,17(7):70-74.
［7］周晓军,闻彩云,王溯源,等.乳腺癌患者动态增强磁共振成像 扩散加权成像影像学特征及其与分子分型的相关性［J］.中国药物与临床,2019,19(23):4040-4043. ZHOU XJ，WEN CY，WANG SY，et al.Imaging characteristics of dynamic enhanced magnetic resonance imaging in breast cancer patients with diffusion-weighted imaging and its correlation with molecular typing［J］.Chinese Journal of Medicine and Clinical Medicine,2019,19(23):4040-4043.
［8］BHIMANI CHANDNI,MATTA DANIELLE,ROTH ROBYN G，et al.Contrast-enhanced spectral mammography:Technique，indications，and clinical applications［J］.Academic Radiology,2017,24(1):84-88.
［9］李明,杨文涛.2015年St.Gallen早期乳腺癌国际专家共识中病理相关问题的解读［J］.中华病理学杂志,2016,45(5):293-296. LI M，YANG WT.Interpretation of pathology-related issues in the international expert consensus of St.Gallen in early breast cancer in 2015［J］.Chinese Journal of Pathology,2016,45(5):293-296.
［10］中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)［J］.中国癌症杂志,2021,31(10):954-1040. Breast cancer Professional Committee of Chinese Anti-Cancer Association.Guidelines and norms for diagnosis and treatment of breast cancer of the Chinese Anti-Cancer Association（2021 edition)［J］.China Oncology,2021,31(10):954-1040.
［11］MERCADO CL.BI-RADS update［J］.Radiologic Clinics of North America,2014,52(3):481-487.
［12］朱雪莉,李芮蝶,陈鑫.乳腺对比增强能谱X线摄影的研究现状［J］.现代肿瘤医学,2022,30(5):923-926. ZHU XL，LI RD，CHEN X.Research status of contra-enhanced energy spectrum radiography of breast［J］.Modern Oncology,2022,30(5):923-926.
［13］杨行,张雪琴,袁元,等.对比增强能谱乳腺X线摄影在致密型乳腺疾病中的诊断价值［J］.影像科学与光化学,2020,38(2):296-300. YANG X，ZHANG XQ，YUAN Y，et al.Comparative enhanced energy spectrum mammography in the diagnosis of dense breast diseases［J］.Image Science and Photochemistry,2020,38(2):296-300.
［14］文婵娟,徐维敏,曾辉,等.对比增强X线摄影对乳腺可疑病变的诊断价值［J］.中华放射学杂志,2019,53(9):737-741. WEN CJ，XU WM，ZENG H，et al.The diagnostic value of contra-enhanced radiography in suspicious breast lesions［J］.Chinese Journal of Radiology,2019,53(9):737-741.
［15］赵钰,李静,冯景.去泛素化酶在ER阳性乳腺癌中作用的研究进展［J］.湖北医药学院学报,2022,41(3):316-319. ZHAO Y，LI J，FENG J.Research progress of deubiquitination enzyme in ER-positive breast cancer［J］.Journal of Hubei University of Medicine,2022,41(3):316-319.
［16］贺新,彭书甲,师弘.乳腺癌患者原发灶与复发转移灶中ER、PR、HER-2及Ki-67表达异质性的回顾性分析［J］.现代肿瘤医学,2023,31(9):1660-1665. HE X，PENG SJ，SHI H.Retrospective analysis of the heterogeneity of ER，PR，HER-2 and Ki-67 expression in primary and metastatic breast cancer patients［J］.Modern Medical，2023,31(9):1660-1665.
［17］何咏竞,孙国平.乳腺癌术后复发时间与临床因素的相关性分析［J］.临床外科杂志,2018,26(1):35-38. HE YJ，SUN GP.Analysis of correlation between postoperative recurrence time and clinical factors of breast cancer［J］.Journal of Clinical Surgery,2018,26(1):35-38.
［18］王希梅,肖春花.TILs预测不同分子分型乳腺癌新辅助化疗疗效的研究进展［J］.天津医科大学学报,2018,24(1):91-93. WANG XM，XIAO CH.Research progress of TILs in predicting the efficacy of neoadjuvant chemotherapy for different molecular types of breast cancer［J］.Journal of Tianjin Medical University,2018,24(1):91-93.
［19］孔汉卿,崔浩,孟德昕,等.HER-2阳性乳腺癌无进展生存期相关临床及超声特征分析［J］.中国超声医学杂志,2022,38(5):509-513. KONG HQ，CUI H，MENG DX，et al.Analysis of clinical and ultrasonic characteristics of progression-free survival in HER-2 positive breast cancer［J］.Chinese Journal of Ultrasound Medicine,2022,38(5):509-513.
［20］TOMIGUCHI M，YAMAMOTO Y，YAMAMOTO-IBUSUKI M，et al.Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer［J］.Cancer Science，2016，107(4):491-498.
［21］SHAO X，WANG X，XU X，et al.Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer［J］.International Journal of Clinical & Experimental Pathology，2014，7(3):1108.
［22］胡波,蔡四忠,常元程,等.相关蛋白在乳腺癌新辅助化疗前后的表达及意义［J］.中国实用医药,2016,11(34):71-73. HU B，CAI SZ，CHANG YC，et al.Expression and significance of related proteins in breast cancer before and after neoadjuvant chemotherapy［J］.Chinese Journal of Practical Medicine,2016,11(34):71-73.
［23］鲍萍萍,彭鹏,顾凯,等.不同分子分型乳腺癌长期预后及治疗对预后的影响:上海乳腺癌生存研究［J］.中华外科杂志,2015,53(12):928-934. BAO PP，PENG P，GU K，et al.Long-term prognosis of different molecular types of breast cancer and the effect of treatment on prognosis:Shanghai breast cancer survival study［J］.Chinese Journal of Surgery,2015,53(12):928-934.
［24］康佳,吴桐,张蕾,等.不同分子分型乳腺癌的多模态超声特征和临床病理对照研究［J］.中华超声影像学杂志,2020,29(4):330-336. KANG J，WU T，ZHANG L，et al.Comparative study of multimodal ultrasound characteristics and clinicopathology in different molecular types of breast cancer［J］.Chinese Journal of Ultrasound Imaging,2020,29(4):330-336.
［25］丁通，孔祥海，杨迎青.4种分子分型乳腺癌的超声特征分析［J］.中国现代医学杂志，2021，31(5):5. DING T，KONG XH，YANG YQ.Ultrasonographic analysis of four molecular types of breast cancer［J］.Chinese Journal of Modern Medicine，2021，31(5):5.
［26］岳林先,主编.实用浅表器官和软组织超声诊断学［M］.北京：人民卫生出版社,2011:278-279. YUE LX（Ed.).Practical ultrasound diagnosis of superficial organs and soft tissues［M］.Beijing:People's Medical Publishing House,2011:278-279.
［27］LIAO HY，ZHANG WW，SUN JY，et al.The Clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer［J］.J Cancer,2018,9(2):296-303.
［28］曾红艳,曹永政,彭格红,等.乳腺癌超声征象与ER、PR、C-erbB-2表达的相关性研究［J］.中国医学影像技术,2007,23(12):1827-1830. ZENG HY，CAO YZ，PENG GH，et al.Study on the correlation between ultrasound signs and expression of ER，PR and C-erbB-2 in breast cancer［J］.Chinese Medical Imaging Technology,2007,23(12):1827-1830.
［29］WOJCINSKI S，STEFANIDOU N，HILLEMANNS P，et al.The biology of malignant breast tumors has an impact on the presentation in ultrasound:An analysis of 315 cases［J］.BMC Women's Health,2013,13(1):47.
［30］周成香,刘健,苟博,等.不同分子分型乳腺癌超声BI-RADS征象分析及其相关性研究［J］.肿瘤预防与治疗,2020,33(11):866-873. ZHOU CX，LIU J，GOU B，et al.Analysis and correlation of ultrasonographic BI-RADS signs in different molecular types of breast cancer［J］.Cancer Prevention and Treatment,2020,33(11):866-873.
［31］刘润,李广林,董燕,等.乳腺癌X线表现与不同分子亚型的相关性分析［J］.实用放射学杂志,2017,33(12):1851-1854,1862. LIU R，LI GL，DONG Y，et al.Correlation analysis between X-ray findings and different molecular subtypes of breast cancer［J］.Journal of Practical Radiology,2017,33(12):1851-1854,1862.
［32］ZHANG L，LI J，XIAO Y，et al.Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision［J］.Sci Rep,2015,5:11085.
［33］MOASSER MM.The oncogene HER-2:Its signaling and transforming functions and its role in human cancer pathogenesis［J］.Oncogene,2007,26(45):6469-6487.
［34］YANG WT，DRYDEN M，BROGLIO K，et al.Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women［J］.Breast Cancer Research and Treatment,2008,111(3):405-410.
［35］WANG D，ZHU K，TIAN J，et al.Clinicopathological and ultrasonic features of triple-negative breast cancers:A comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers［J］.Ultrasound Med Biol,2018,44(5):1124-1132.
［36］BOISSERIE-LACROIX M，MACGROGAN G，DEBLED M，et al.Triple-negative breast cancers:Associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers［J］.The Oncologist,2013,18(7):802-811.
［37］黄旋.不同分子分型浸润性乳腺癌彩色多普勒超声图像特征对比研究［D］.福州:福建医科大学,2014. HUANG X.Comparative study on characteristics of color Doppler ultrasound images of invasive breast cancer with different molecular types［D］.Fuzhou:Fujian Medical University,2014.
［38］HASAN R，BHATT D，KHAN S，et al.Association of Her-2 expression and clinicopathological parameters in colorectal carcinoma in Indian population［J］.Open Access Maced J Med Sci,2018,7(1):6-11.
［39］王婷婷,周娟,田宁,等.乳腺癌钼靶、MRI征象与分子分型的相关性分析［J］.磁共振成像,2019,10(6):420-424. WANG TT，ZHOU J，TIAN N，et al.Correlation analysis of mammography，MRI signs and molecular typing of breast cancer［J］.Magnetic Resonance Imaging,2019,10(6):420-424.
［40］DROMAIN C，THIBAULT F，MULLER S，et al.Dual-energy contrast-enhanced digital mammography:Initial clinical results［J］.European Radiology,2011,21(3):565-574.
［41］HOUBEN IPL，VAN DE VOORDE P，JEUKENS CRLPN，et al.Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits［J］.European Journal of Radiology,2017,94:31-37.

Memo

Memo:
广东省广州市科技计划项目（编号：202002030217）
Last Update: 2023-09-28